Terns Pharmaceuticals, Inc. Common Stock
TERNTerns Pharmaceuticals, Inc. is a biotechnology company focused on developing innovative therapies for metabolic and liver diseases. Based in the United States, the company leverages precision medicine and advanced research techniques to create targeted treatments aimed at unmet medical needs in conditions such as non-alcoholic steatohepatitis (NASH) and related metabolic disorders.
Company News
Terns Pharmaceuticals plans to raise $650 million through a public offering of 16,250,000 shares at $40.00 per share, with proceeds intended to fund research, clinical trials, and development of product candidates like TERN-701.
Terns Pharmaceuticals reported promising Phase 1 clinical trial results for TERN-701, an investigational BCR::ABL1 inhibitor for chronic myeloid leukemia (CML), showing 64-75% major molecular response rates and a favorable safety profile across patient subgroups.
Commodore Capital initiated a $42.8 million stake in Terns Pharmaceuticals during Q3, representing 2.1% of its reportable assets. The biotech company has shown promising early efficacy data for its oncology program and is preparing for an upcoming presentation at the American Society of Hematology.
Terns Pharmaceuticals has a promising GLP-1 weight-loss drug that could compete with treatments from Novo Nordisk and Eli Lilly. However, the company is still in early stages and faces risks, including the need for ongoing stock offerings to fund its cash-burning operations.
Terns Pharmaceuticals, a pre-revenue weight loss biotech company, is worth considering as its lead candidate TERN-601 has shown promising phase 1 results, suggesting it could be competitive with other weight loss drugs on the market.
